MRUS Merus N.V.

12.46
+0.42  (+3%)
Previous Close 12.04
Open 11.95
Price To Book 2.67
Market Cap 282004688
Shares 22,632,800
Volume 7,944
Short Ratio
Av. Daily Volume 42,390

NewsSee all news

  1. Is Merus NV (NASDAQ:MRUS) A Financially Sound Company?
  2. Merus N.V. (MRUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  3. Merus to Present at the Jefferies 2018 London Healthcare Conference
  4. Merus Strengthens Team with Key Appointments
  5. Merus N.V. : Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018

SEC filingsSee all SEC filings

  1. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181206277
  2. CT ORDER - Confidential treatment order 181153195
  3. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181008479
  4. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 18974406
  5. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 18973191

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 commencement of dosing announced January 26, 2018.
MCLA-128
Breast cancer - HER2-positive MBC and ER+/HER2-low MBC
Phase 1/2 gastric data presented at ESMO 2018.
MCLA-128
Gastric cancer, ovarian, endometrial and non-small cell lung cancer
Phase 1 early activity data is expected 4Q 2018.
MCLA-117
Acute Myeloid Leukemia
Phase 1 dosing announced May 24, 2018.
MCLA-158
Colorectal cancer

Latest News

  1. Is Merus NV (NASDAQ:MRUS) A Financially Sound Company?
  2. Merus N.V. (MRUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  3. Merus to Present at the Jefferies 2018 London Healthcare Conference
  4. Merus Strengthens Team with Key Appointments
  5. Merus N.V. : Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018
  6. Merus Announces Annual Meeting of Shareholders
  7. Merus to Present at the Jefferies 2018 Healthcare Conference
  8. Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors

SEC Filings

  1. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181206277
  2. CT ORDER - Confidential treatment order 181153195
  3. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181008479
  4. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 18974406
  5. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 18973191
  6. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 18970431
  7. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 18941176
  8. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 18931157
  9. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 18907922
  10. CT ORDER - Confidential treatment order 18849430